MiMedx Group, Inc. — Q3 2020 Form 10-Q Summary
Business context and reporting period
MiMedx develops, manufactures, and markets human placental tissue allografts for advanced wound care, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental applications. The filing covers the three and nine months ended September 30, 2020. Results were affected by COVID-19, ongoing litigation and regulatory matters, remediation of prior-period revenue-recognition and internal-control issues, and a July 2020 refinancing and preferred-stock issuance.
Key financial metrics
| Metric | Q3 2020 | Q3 2019 | 9M 2020 | 9M 2019 |
|---|---|---|---|---|
| Net sales | $64.3 million | $88.9 million | $179.7 million | $222.9 million |
| Gross profit | $54.0 million | $75.7 million | $151.2 million | $192.5 million |
| Gross margin | 84.0% | 85.1% | 84.1% | 86.4% |
| Net income (loss) | $(19.4) million | $12.4 million | $(32.7) million | $(18.1) million |
| Adjusted EBITDA | $6.9 million | $7.6 million | $20.3 million | $28.0 million |
| Operating cash flow | Not separately provided | Not separately provided | $(20.0) million | $(16.3) million |
Q3 net loss available to common stockholders was $52.0 million, or $0.48 per basic and diluted share, including approximately $32.6 million of preferred-stock dividends and deemed dividends. Nine-month loss available to common stockholders was $65.3 million, or $0.60 per share.
At September 30, 2020, cash and cash equivalents were $109.6 million, current assets were $171.5 million, current liabilities were $57.3 million, and the current ratio was approximately 3.0. Net debt consisted primarily of a $50.0 million Hayfin term loan, recorded net at $47.6 million. The related $25.0 million delayed-draw facility was undrawn.
Material changes versus the prior comparable period
- Reported Q3 sales declined 27.6% and nine-month sales declined 19.4%; however, comparisons were distorted by the October 2019 change from a cash-receipts-based approach for certain legacy arrangements to primarily as-shipped revenue recognition. Adjusted net sales declined 6.2% in Q3 and 14.4% for nine months.
- Gross margins decreased because of higher CGMP quality standards, lower manufacturing yields, and unfavorable product mix.
- Q3 investigation, restatement, and related expenses increased to $12.0 million from $7.2 million. Nine-month expense declined to $39.1 million from $46.4 million.
- The Company recorded an $8.2 million loss on extinguishment of the Blue Torch term loan after refinancing with Hayfin and issuing Series B preferred stock.
- On July 2, 2020, MiMedx issued $100 million of Series B convertible preferred stock and entered into a $50 million senior secured term loan. These transactions funded debt repayment, working capital, capital expenditures, and strategic initiatives.
- The Company recognized an $11.3 million income-tax benefit related primarily to CARES Act net operating loss carryback provisions and expects a federal tax refund of approximately $11.3 million.
Guidance, outlook, risks, contingencies, and unusual items
- Management expects cash from operations, existing cash, and the July financing transactions to fund operating and investing needs for the 12 months from November 4, 2020, including potential COVID-19-related challenges.
- Management expects additional research and development and regulatory-compliance spending, including work on INDs, BLAs, CGMP compliance, clinical trials, and micronized dHACM programs.
- Management reported progress in launching an expandable EpiCord product and completing enrollment in Phase 2B knee osteoarthritis and Phase 3 plantar fasciitis studies.
- COVID-19 reduced healthcare-provider access, patient visits, and sales-force activity. Future waves could adversely affect demand, clinical trials, manufacturing, collections, and liquidity, although management reported only modest manufacturing disruption through September 30.
- The Hayfin loan bears interest at LIBOR plus 6.75%, subject to a 1.5% LIBOR floor, and matures July 2, 2025. It includes maximum leverage and minimum liquidity covenants; the Company reported compliance at September 30, 2020.
- Series B preferred stock carries a 4.0% cumulative dividend initially and 6.0% thereafter, is convertible at $3.85 per common share, and has a liquidation preference. The Company elected to accrue, rather than pay, approximately $1.0 million of the September 30 dividend.
- Legal and regulatory matters remain material. The Company had accrued $7.6 million for legal proceedings and paid $7.4 million toward legal matters during the first nine months. Matters include shareholder derivative actions, securities litigation, government investigations, qui tam litigation, and former-employee claims.
- Disclosure controls and procedures were not effective as of September 30, 2020 because of unremediated material weaknesses in internal control over financial reporting. Management continued remediation efforts during the quarter.
- The filing provides no formal revenue or earnings guidance. The common stock resumed Nasdaq trading on November 4, 2020 under the symbol MDXG.
Most important facts for investors to verify
- Reconcile reported sales with adjusted sales and understand the continuing impact of the revenue-recognition transition and the remaining $1.8 million of unrecognized legacy-contract sales at September 30, 2020.
- Assess whether cash generation can support ongoing legal, regulatory, clinical, CGMP, and operating expenditures despite nine-month operating cash usage of $20.0 million.
- Review Hayfin covenant thresholds, variable-rate exposure, refinancing terms, prepayment premiums, and the undrawn delayed-draw facility.
- Evaluate the economic and potential dilution effects of the Series B preferred stock, including accrued dividends, conversion into approximately 26.2 million common shares as of September 30, and board and voting rights.
- Monitor the resolution and cash impact of litigation, government investigations, indemnification obligations, and the shareholder derivative settlement pending final approval.
- Verify management’s remediation of material weaknesses and whether disclosure controls and internal control over financial reporting become effective in subsequent filings.